Listen to the article 11 min This audio is auto-generated. Please let us know if you have feedback. After roughly three years of navigating the
Dive Brief: Dexcom plans to launch a new continuous glucose monitor this summer for people with Type 2 diabetes who don’t take insulin. The device,
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Susan Tousi, CEO of Delfi Diagnostics Courtesy of
Canopy Growth Announces US$30 Million Private Placement SMITHS FALLS, ON, Jan. 9, 2024 /PRNewswire/ – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED)
Record Q2 Net Revenue of $194 Million, Increases 34% Over the Prior Year Period Global Cannabis Leader with #1 Market Share in Canada and 31%
Share this article Astellas is working closely with the FDA and the third-party manufacturer to address the flagged deficiencies. Credits: JHVEPhoto/Shutterstock.com The US Food and
SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in
A non-invasive, low-cost lung cancer detection platform called PATROL.
“A response can be expected within 30 business days after the Panel meeting”, according to the Attorney General’s office. That’s up to six weeks without